Blog
RSS FeedPosted by Michael Wonder on 24 Jan 2022
Health Canada approves Ipsen’s Sohonos (palovarotene) as the first approved treatment for fibrodysplasia ossificans progressiva
24 January 2022 - Ipsen today announced the Health Canada approval of Sohonos (palovarotene), an oral selective retinoic-acid receptor gamma agonist ...
Posted by Michael Wonder on 18 Jan 2022
Canada approves Pfizer COVID drug
18 January 2022 - Canada’s health regulator has approved a pill by Pfizer that treats the effects of COVID-19. ...
Posted by Michael Wonder on 13 Jan 2022
Quebec to impose health tax on unvaccinated Canadians
12 January 2022 - The Canadian province of Quebec will charge a health tax to residents who are not vaccinated ...
Posted by Michael Wonder on 13 Jan 2022
JAMP and Alvotech announce Canadian approval of Simlandi, a high concentration biosimilar to Humira, providing access to previously unavailable versions in Canada
10 January 2021 - Health Canada rules that 40 mg/0.4 mL and 80 mg/0.8 mL presentations of Simlandi are not subject ...
Posted by Michael Wonder on 31 Dec 2021
Celltrion acquires approval for its new Humira 'Yuflyma' in Canada
30 December 2021 - Celltrion announced on December 30 that it won marketing approval from Health Canada for "Yuflyma", a ...
Posted by Michael Wonder on 26 Dec 2021
SIGA announces Health Canada regulatory approval of oral TPOXX
1 December 2021 - SIGA Technologies today announced that Health Canada has approved oral Tpoxx (tecovirimat) as an extraordinary use new ...
Posted by Michael Wonder on 26 Dec 2021
GSK’s Jemperli (dostarlimab for injection) approved in Canada as an anti-PD-1 therapy for recurrent or advanced endometrial cancer
15 December 2021 - GSK announces today that it has been granted Notice of Compliance with conditions for its endometrial ...
Posted by Michael Wonder on 15 Dec 2021
Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Quebec and Nova Scotia
15 December 2021 - Public reimbursement now includes Alberta, Quebec and Nova Scotia, representing approximately 37% of the Canadian population. ...
Posted by Michael Wonder on 10 Dec 2021
VBI Vaccines announces filing of new drug submission for 3 antigen hepatitis B vaccine to Health Canada
9 December 2021 - VBI Vaccines today announced the filing of a new drug submission to Health Canada for the Company’s ...
Posted by Michael Wonder on 09 Dec 2021
Canada's national strategy for drugs for rare diseases needs a holistic approach
8 December 2021 - International report summarises drugs for rare disease best practices and recommendations. ...
Posted by Michael Wonder on 02 Dec 2021
Pfizer Canada initiates submission to Health Canada for COVID-19 oral anti-viral candidate
1 December 2021 - Pfizer Canada today initiated the filing of a rolling new drug submission with Health Canada for its ...
Posted by Michael Wonder on 01 Dec 2021
Lilly Canada concludes successful negotiation with the Pan-Canadian Pharmaceutical Alliance for Baqsimi (glucagon nasal powder)
30 November 2021 - Lilly Canada is pleased to announce the completion of a successful negotiation with the pan-Canadian Pharmaceutical Alliance ...
Posted by Michael Wonder on 27 Nov 2021
What happened to the promise of universal pharmacare?
25 November 2021 - Canada is the only developed country in the world with a universal health care system that ...
Posted by Michael Wonder on 27 Nov 2021
It’s time to better support the three million Canadians with a rare disease
25 November 2021 - After finding out her private health insurer would no longer pay for a drug helping with ...
Posted by Michael Wonder on 27 Nov 2021
Shingrix approved in Canada for adults at increased risk of shingles due to immunodeficiency or immunosuppression
25 November 2021 - GlaxoSmithKline today announced that Shingrix (Zoster Vaccine Recombinant, Adjuvanted) has been approved in Canada for the prevention ...